Despite lower potency against the moderate Her2 expressing 361 cell lines, we wanted to evaluate these ADCs in vivo in an N87 gastric cancer xenograft model due to their potent in vitro activity against the N87 cell line. This evidence concerns the gene ERBB2 and gastric cancer.